Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
June 08, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis to Present at the Jefferies Healthcare Conference
June 02, 2016 07:15 ET
|
Curis, Inc.
LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting
June 02, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints
June 01, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
Curis Reports First Quarter 2016 Financial Results
May 09, 2016 08:00 ET
|
Curis, Inc.
LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016
May 02, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for...
Curis and Aurigene Present Preclinical Data from Multiple Programs at AACR Annual Meeting
April 20, 2016 09:00 ET
|
Curis, Inc.
LEXINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug...
Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting
April 11, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
April 04, 2016 07:00 ET
|
Curis, Inc.
-- Latest analysis of data presented at the American Society of Hematology’s annual meeting in December, 2015 ---- CUDC-907 demonstrated objective responses, including complete responses, in...
Curis Announces Expansion of Executive Team
March 30, 2016 07:00 ET
|
Curis, Inc.
-- James Dentzer joins Curis as Chief Financial and Chief Administrative Officer ---- David Tuck, M.D. is promoted to Chief Medical Officer and Mani Mohindru, Ph.D. is promoted to Chief Strategy...